Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.04Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 20, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook for Dynavax, highlighted by record revenue growth, market leadership in hepatitis B vaccines, and promising clinical advancements. However, challenges remain in the approval of the hemodialysis vaccine and increasing R&D expenses.Company Guidance
During Dynavax Technologies' fourth quarter and full year 2024 financial results conference call, the company provided guidance for 2025, expecting HEPLISAV-B net product sales to reach between $305 million to $325 million, driven by an expanding adult hepatitis B vaccine market and anticipated market share gains. HEPLISAV-B's market share reached 44% by the end of 2024, with net revenues totaling $71 million for the fourth quarter and $268 million for the full year. The company foresees the adult hepatitis B vaccine market expanding to over $900 million by 2030, with HEPLISAV-B capturing at least 60% market share. For 2025, Dynavax projects adjusted EBITDA, excluding stock-based compensation, to be at least $75 million, demonstrating growth at more than twice the rate of product revenue. The company also plans to advance its shingles vaccine program, with a Phase I/II study readout expected in the third quarter of 2025, aiming to establish proof of concept and prepare for a Phase III global launch.Record HEPLISAV-B Revenue Growth
HEPLISAV-B achieved record net revenues of $71 million for Q4 and $268 million for the full year 2024, reflecting a 39% and 26% increase year-over-year, respectively.
Market Share Leadership in Hepatitis B Vaccine
HEPLISAV-B increased its market share to 44% by the end of 2024, becoming the market leader in the U.S. hepatitis B adult vaccine market.
Positive Market Dynamics for HEPLISAV-B
Medicare policy changes and the inclusion of hepatitis B vaccination in HEDIS measures are expected to boost market share and revenue growth for HEPLISAV-B in 2025.
Strong Financial Performance and Guidance
Dynavax achieved profitability with a net income of $27 million for 2024. The company also set guidance for 2025 with expected HEPLISAV-B net product revenue between $305 million to $325 million.
Clinical Pipeline Advancements
The shingles vaccine program, Z-1018, showed promising Phase I results with favorable tolerability compared to Shingrix and is advancing to a Phase I/II study.
---
DVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 20, 2025 | $13.33 | ― | ― |
| Nov 07, 2024 | $12.02 | $13.01 | +8.24% |
| Aug 06, 2024 | $10.05 | $10.75 | +6.97% |
| May 08, 2024 | $11.65 | $11.01 | -5.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Dynavax Technologies Corp. (DVAX) report earnings?
Dynavax Technologies Corp. (DVAX) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Dynavax Technologies Corp. (DVAX) earnings time?
Dynavax Technologies Corp. (DVAX) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DVAX EPS forecast?
DVAX EPS forecast for the fiscal quarter 2024 (Q4) is 0.04.
---